Apixaban lowers the risk of stroke compared to warfarin in anticoagulationnaive patients with atrial fibrillation scheduled for elective cardioversion, according to latebreaking results from. The primary objective was to compare apixaban to heparinvitamin k antagonist vka in patients with atrial fibrillation af and. Emanate is a descriptive study without hypothesis testing. Findings from the emanate trial presented at esc congress 2017 in barcelona suggest the use of apixaban lowers the risk of stroke compared with warfarin in patients with atrial fibrillation afib undergoing cardioversion. Jul 19, 2014 the emanate trial is anticipated to enroll 1,500 eligible patients from the us, canada, europe and asia. Rates of bleeding were similar between the two groups. Longterm treatment of cancer associated vte optimal dose. The emanate study supports the use of apixaban in patients with af undergoing cardioversion. Clinical trial results are important because they can help doctors consider and choose the right treatment for you based on their efficacy and safety results.
In may 2018, following results from the annexa4 trial, the us food and drug administration approved andexanet alfa as the first specific antidote for the antixa inhibitors apixaban and rivaroxaban when reversal of anticoagulant effects is required in lifethreatening or uncontrolled bleeding. Do noacs ensure safe cardioversion in atrial fibrillation. Aug 28, 2017 apixaban lowers the risk of stroke compared to warfarin in anticoagulationnaive patients with atrial fibrillation scheduled for elective cardioversion, according to new research. The emanate trial is anticipated to enroll 1,500 eligible patients from the us, canada, europe and asia. Apixaban vs conventional therapy in anticoagulation.
Apixaban compared with parenteral heparin andor vitamin k. Apixaban lowers stroke risk in atrial fibrillation. The safea study is the first randomized controlled trial to compare 1month vs. Apixaban compared with parenteral heparin and or vitamin k antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion. Phase iv emanate trial enrollment begins to assess. Study of the blood thinner, apixaban, for patients who. Also, the 1500patient openlabel emanate trial supports an accelerated cardioversion schedule in which the procedure can be performed as soon as 2 hours after the start of bolusdosed apixaban. Management of direct oral anticoagulants in patients with. Apixaban lowers stroke risk during cardioversion the eliquis evaluated in acute cardioversion compared to usual treatments for anticoagulation in subjects with nvaf emanate trial examined eliquis apixaban versus conventional therapy in patients with atrial fibrillation undergoing cardioversion. It was a doubleblind, randomizedcontrolled trial comparing the use of apixaban with aspirin two thirds received lowdose aspirin for prevention of stroke or systemic embolism among. Apixaban compared to heparinvitamin k antagonist in patients with atrial fibrillation scheduled for cardioversion. Patients with atrial fibrillation who received apixaban before their scheduled cardioversion had a lower risk for stroke compared with warfarin and heparin, according to the emanate study.
Catheter ablation is an effective and increasingly used component of rhythm control therapy to improve symptoms in patients with atrial fibrillation. Backgroundvitamin k antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. The purpose of the emanate 2 trial was to compare the rates of stroke and bleeding with apixaban versus warfarin with heparin in. Apixaban lowers stroke risk in atrial fibrillation patients undergoing.
Ezekowitz md1, pollack cv2, sanders p3, halperin jl4, spahr j5, cater n6, petkun w7, breazna a6, kirchhof p8, oldgren j9. Bleeding rates were similar across both the apixaban and warfarin groups. Rationale and design of the emanate trial author links open overlay panel michael d. The editorialists highlight important outstanding issues. Bristolmyers squibb and pfizer announce enrollment of first. Apixaban to prevent stroke in patients with atrial. Researchers randomized 1,500 afib patients to either apixaban or parenteral heparin with warfarin. September 1, 2017 apixaban lowers the risk of stroke compared to warfarin in anticoagulationnaive patients with atrial fibrillation scheduled for elective cardioversion, according to latebreaking results from the emanate trial presented in a hot line lbct session at esc congress. Apixaban in patients at risk of stroke undergoing atrial. Apixaban is a novel oral direct factor xa inhibitor that.
Apixaban lowers stroke risk in af patients undergoing. Ezekowitz, professor, sidney kimmel medical college at thomas jefferson university, philadelphia, pa and lankenau heart center, wynnewood, pa and bryn mawr hospital, bryn mawr, pa. Apixaban versus heparinvitamin k antagonist in anticoagulationnaive patients with atrial fibrillation scheduled for cardioversion. Rationale and design of the emanate trial, american heart journal on deepdyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips. Longterm treatment of cancer associated vte optimal dose of. The novelty of this trial was the exclusive enrolment of anticoagulantnaive patients 62% not receiving, 38% aug 28, 2017 princeton, n. Apixaban compared to heparinvitamin k antagonist in patients with. Pollack, md, ma, c paul sanders, phd, d jonathan l. Pfe today presented findings from emanate eliquis evaluated in acute cardioversion compared to usual treatments for anticoagulation in subjects with nvaf, a phase 4 clinical trial, during a latebreaking hot line presentation at. Apixaban lowers stroke risk in atrial fibrillation patients undergoing cardioversion 28 august 2017 apixaban lowers the risk of stroke compared to warfarin in anticoagulationnaive patients with. However, in this study subjects who underwent cardioversion had already. Randomized openlabel trials comparing rivaroxaban and edoxaban.
The goal of the trial was to evaluate shortduration apixaban compared with warfarin with among patients with atrial fibrillation undergoing cardioversion. In addition, the emanate trial, 17 which studied 840 patients with toe prior to ecv of af, found lat in 7. Read apixaban compared with parenteral heparin andor vitamin k antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion. In the meantime, noacs can be safely used in clinical practice to prevent thromboembolic events in patients with atrial fibrillation undergoing elective. Also, the 1500patient openlabel emanate trial supports an accelerated cardioversion schedule in which the procedure can be performed as soon as 2.
Dabigatran apixaban rivaroxaban warfarin adjusted hr 95% ci vs warfarin allcause mortality 0 2 4 6 8 10 d a r w hr 0. In early 2011, the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin k antagonist treatment averroes trial was published. Rationale and design of the emanate trial michaeld. Further information about the safety and efficacy of other noacs will be provided by findings from the ongoing emanate trial nct02100228 of apixaban versus vitamin k antagonist plus heparin. Pdf apixaban compared with parenteral heparin and or. Bristolmyers squibb and pfizer announce enrollment of. Sep 01, 2016 read apixaban compared with parenteral heparin andor vitamin k antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion. Use of direct oral anticoagulants among patients undergoing. The primary efficacy objective is to determine whether a lowdose regimen of apixaban 2. Apixaban lowers stroke risk in atrial fibrillation patients. Apixaban lowers stroke risk during cardioversion the eliquis evaluated in acute cardioversion compared to usual treatments for anticoagulation in subjects with nvaf emanate trial examined eliquis apixaban versus conventional therapy. Apixaban eliquis is a new direct oral factor xa inhibitor. Apixaban versus warfarin in patients with atrial fibrillation.
Apixaban compared to heparinvitamin k antagonist in. The emanate eliquis evaluated in acute cardioversion compared to usual treatments for anticoagulation in subjects with atrial fibrillation trial is a randomized, prospective, open. Af patients less than 48 hours of anticoagulation who were scheduled for cardioversion randomized to apixaban or heparin with warfarin. Michael d ezekowitz, charles v pollack, jr, jonathan l halperin, richard d england, sandra vanpelt nguyen, judith spahr, maria sudworth, nilo b cater, andrei breazna, jonas oldgren, paulus kirchhof, apixaban compared to heparinvitamin k antagonist in patients with atrial fibrillation scheduled for cardioversion.
The next phase in anticoagulation for cardioversion of. Emanate trial adds to the insights from the xtra study and the clot af registry by systematically evaluating the use of a nonvka in the setting of imageidentified left atrial thrombus. The primary endpoint is the incidence of all bleeding complications occurring within 12 months. A phase iv trial to assess the effectiveness of apixaban. Apixaban compared to heparinvitamin k antagonist in patients. Apixaban is a blood thinner that works by stopping one of the blood substances required for clotting factor xa. Apixaban compared with parenteral heparin andor vitamin k antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion. Most embolic events occur within 10 days of cardioversion. Pdf management of direct oral anticoagulants in patients. Emanate, a randomized, openlabel clinical trial, will assess the effectiveness and safety of eliquis compared with usual care parenteral heparin andor oral anticoagulation with a vitamin k antagonist initiated in patients with nvaf expected to undergo cardioversion after shortterm anticoagulation, in a clinical practice setting. Study of the blood thinner, apixaban, for patients who have.
Ezekowitz md, pollack cv jr, halperin jl, england rd, vanpelt nguyen s, spahr j, sudworth m, cater nb, breazna a, oldgren j, kirchhof p. Study of the blood thinner, apixaban, for patients who have an. In a subgroup analysis of aristotle trial data, 743cardioversions were performed in 540subjects, and the effectivenessof apixaban was demonstrated in the 30 days following cardioversion. Mar 31, 2014 ezekowitz md, pollack cv jr, halperin jl, england rd, vanpelt nguyen s, spahr j, sudworth m, cater nb, breazna a, oldgren j, kirchhof p. A total of 5,400 patients were enrolled and randomized to treatment with apixaban or conventional therapy i. After electrical cardioversion, thromboembolic risk increases incrementally because of left atrial stunning and subsequent recovery of function, resulting in thrombus dislodgement. Cardioversion of recent onset af in an anticoagulationnaive patient. Nct02100228 atrial fibrillation clinical trial pfizer. In a clinical trial, eliquis was tested against lovenox enoxaparin followed by warfarin lovenox warfarin, a standard treatment, for the first 6 months after dvtpe. Phase iv, multicenter, randomized, open label trial. The purpose of the emanate 2 trial was to compare the rates of stroke and bleeding with apixaban versus warfarin with heparin in anticoagulationnaive defined as having received less than 48 hours of anticoagulation therapy patients scheduled for elective cardioversion of predominately new onset nonvalvular atrial fibrillation.
260 52 1207 1615 848 1099 1222 1079 493 520 145 814 551 1305 1157 930 1539 524 130 1131 355 1568 402 427 538 506 1084 686 1203 1437 102 575 249 445 751